BRIEF-Aquestive Therapeutics Announces That FDA Will Not Require An Advisory Committee Meeting To Discuss New Drug Application For Anaphylm™

Reuters

Sep 04

BRIEF-Aquestive <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces That FDA Will Not Require An Advisory Committee Meeting To Discuss New Drug Application For Anaphylm™

Aquestive Therapeutics Inc AQST.O:

AQUESTIVE THERAPEUTICS ANNOUNCES THAT FDA WILL NOT REQUIRE AN ADVISORY COMMITTEE MEETING TO DISCUSS NEW DRUG APPLICATION FOR ANAPHYLM™
AQUESTIVE THERAPEUTICS INC - PDUFA TARGET ACTION DATE FOR ANAPHYLM IS JANUARY 31, 2026

Source text: ID:nGNX8SqwGh

Further company coverage: AQST.O

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2564337615"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2564337615\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2564337615?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-04 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564337615","market":"us","top_or_hot":-1,"title":"BRIEF-Aquestive Therapeutics Announces That FDA Will Not Require An Advisory Committee Meeting To Discuss New Drug Application For Anaphylm™","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Aquestive <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces That FDA Will Not Require An Advisory Committee Meeting To Discuss New Drug Application For Anaphylm™</title></head><body><p>Aquestive Therapeutics Inc <span>AQST.O</span>:</p><ul><li><p>AQUESTIVE THERAPEUTICS ANNOUNCES THAT FDA WILL NOT REQUIRE AN ADVISORY COMMITTEE MEETING TO DISCUSS NEW DRUG APPLICATION FOR ANAPHYLM™</p></li><li><p>AQUESTIVE THERAPEUTICS INC - PDUFA TARGET ACTION DATE FOR ANAPHYLM IS JANUARY 31, 2026</p></li></ul><p>Source text: <span>ID:nGNX8SqwGh</span></p><p>Further company coverage: <span>AQST.O</span></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Aquestive Therapeutics Announces That FDA Will Not Require An Advisory Committee Meeting To Discuss New Drug Application For Anaphylm™</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Aquestive Therapeutics Announces That FDA Will Not Require An Advisory Committee Meeting To Discuss New Drug Application For Anaphylm™\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-04 19:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Aquestive <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces That FDA Will Not Require An Advisory Committee Meeting To Discuss New Drug Application For Anaphylm™</title></head><body><p>Aquestive Therapeutics Inc <span>AQST.O</span>:</p><ul><li><p>AQUESTIVE THERAPEUTICS ANNOUNCES THAT FDA WILL NOT REQUIRE AN ADVISORY COMMITTEE MEETING TO DISCUSS NEW DRUG APPLICATION FOR ANAPHYLM™</p></li><li><p>AQUESTIVE THERAPEUTICS INC - PDUFA TARGET ACTION DATE FOR ANAPHYLM IS JANUARY 31, 2026</p></li></ul><p>Source text: <span>ID:nGNX8SqwGh</span></p><p>Further company coverage: <span>AQST.O</span></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AQST","symbol_name":"Aquestive Therapeutics Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250904:nTUA4QPZYT:1","article_id":"2564337615","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564337615","pubTimestamp":1756983686,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Aquestive Therapeutics Announces That FDA Will Not Require An Advisory Committee Meeting To Discuss New Drug Application For AnaphylmAquestive Therapeutics Inc AQST.O:AQUESTIVE THERAPEUTICS ANNO","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AQST":"Aquestive Therapeutics Inc.","BK4007":"制药"},"translate_title":"简报-Aquestive Therapeutics宣布FDA不会要求召开咨询委员会会议来讨论Anaphylm的新药申请™","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AQST":0.9},"content_text":"BRIEF-Aquestive Therapeutics Announces That FDA Will Not Require An Advisory Committee Meeting To Discuss New Drug Application For Anaphylm™Aquestive Therapeutics Inc AQST.O:AQUESTIVE THERAPEUTICS ANNOUNCES THAT FDA WILL NOT REQUIRE AN ADVISORY COMMITTEE MEETING TO DISCUSS NEW DRUG APPLICATION FOR ANAPHYLM™AQUESTIVE THERAPEUTICS INC - PDUFA TARGET ACTION DATE FOR ANAPHYLM IS JANUARY 31, 2026Source text: ID:nGNX8SqwGhFurther company coverage: AQST.O","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}